Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Anatara Lifesciences Ltd ( (AU:ANR) ).
Anatara Lifesciences Ltd has announced the completion of Stage 2 of its Phase II GaRP-IBS trial, revealing that while the primary efficacy endpoint was not met, significant findings were observed. The trial showed no safety concerns, and secondary endpoints indicated improvements in anxiety scores and IBS-Adequate Relief, suggesting potential benefits to the gut-brain axis. The company plans to leverage these findings for commercial opportunities and is also progressing with its anti-obesity project.
More about Anatara Lifesciences Ltd
Anatara Lifesciences Ltd is a developer of evidence-based, innovative products focused on addressing significant unmet needs in human health, particularly conditions involving the complexity of the gastrointestinal tract.
YTD Price Performance: -78.00%
Average Trading Volume: 1,197,997
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$1.28M
See more data about ANR stock on TipRanks’ Stock Analysis page.